LBTSF News and Press, Almirall Sa Ord From 07/27/20

BARCELONA, Spain , July 27, 2020 /PRNewswire/ -- Key growth drivers continue to show positive results. Ilumetri ®  performed strongly despite a decrease in new patient initiations during the COVID-19 pandemic, while Skilarence ®  results matched expectation...

Almirall, S.A. (LBTSF) Q1 2020 Earnings Conference Call May 11, 2020 04:00 AM ET Company Participants Pablo Divasson del Fraile - Chief Investor Relations and Corporate Communications Peter Guenter - CEO Mike McClellan - EVP and CFO Amita Kent - General Counsel Bhushan Hardas...

Almirall, S.A. (LBTSF) Q4 2019 Results Earnings Conference Call February 24, 2020, 04:00 AM ET Company Participants Pablo Divasson del Fraile - Chief Investor Relations and Corporate Communications Peter Guenter - Chief Executive Officer Bhushan Hardas - Executive Vice President...

The following slide deck was published by Almirall, S.A. in conjunction with their 2019 Q4 earnings Read more ...

Almirall, S.A. ( OTC:LBTSF ): Q4 net income of €136.1M Revenue of €908.4M (+12.0% Y/Y) Press Release More news on: Almirall, S.A., Earnings news and commentary, Healthcare stocks news,

Almirall S.A. ( OTC:LBTSF ) is starting the new year with a flurry of deals. More news on: Almirall, S.A., Wuxi Biologics (Cayman) Inc ADR, WuXi Biologics (Cayman) Inc., Healthcare stocks news, Read more ...

Almirall, S.A. (LBTSF) Q3 2019 Earnings Conference Call November 11, 2019 4:00 AM ET Company Participants Pablo Divasson del Fraile – Chief Investor Relations and Corporate Communications Peter Guenter – Chief Executive Officer Bhushan Hardas – Executive Vice...

The following slide deck was published by Almirall, S.A. in conjunction with their 2019 Q3 earnings Read more ...

Almirall, S.A. ( OTC:LBTSF ): 9M net income of €97.3M More news on: Almirall, S.A., Earnings news and commentary, Healthcare stocks news, Read more ...

Quick Take Cabaletta Bio ( CABA ) has filed to raise $87 million in an IPO of its common stock, according to an S-1/A registration statement . The firm is developing drug treatments for Pemphigus and other autoimmune conditions. CABA is an ultra-high-risk pre-Phase 1 stage biopharma, an...